<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175149</url>
  </required_header>
  <id_info>
    <org_study_id>EX 0203 DK</org_study_id>
    <nct_id>NCT00175149</nct_id>
  </id_info>
  <brief_title>Active Vitamin D Effect on Left Ventricular Hypertrophy</brief_title>
  <official_title>The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Ivarsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of
      LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH. In
      the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to
      study the effect on LVH.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of dihydroxycholecalciferol on left ventricular hypertrophy</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the activity of the renin-angiotensin system</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular function</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Given alfacalcidiol. Dose adjusted after PTH level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The untreated arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfacalcidiol</intervention_name>
    <description>Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease (S-creatinin &gt; 150 and &lt; 600 mikroM)

          -  Secondary hyperparathyroidism (Between 3-8 times the upper limit of our PTH assay)

          -  Stable blood pressure during the last 6 months (less than (160/95)

          -  B-hemoglobin &gt; 6 mmol/l

          -  EKG with sinus rhythm and no sign of Q-wave infarction

          -  Expected follow up 6 month

        Exclusion Criteria:

          -  Pregnancy

          -  Kidney transplantation

          -  Malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Ivarsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deparment of Renam Medicine C, Skejby Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Ivarsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deparment of Renal Medicine C, Skejby Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Renal Medicne C, Skejby Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>December 6, 2015</last_update_submitted>
  <last_update_submitted_qc>December 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Per Ivarsen</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>CKD 3-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

